B cell-directed therapies in multiple sclerosis

Neurodegenerative disease management

Volumn 6, Issue 1, 2016, Pages 37-47

  Gasperi, Christiane ^a   Stüve, Olaf ^a   Hemmer, Bernhard ^a  

^a Technische Universität München Munich Cluster for Systems Neurology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB;

B LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; HUMAN; IMMUNOLOGY; MULTIPLE SCLEROSIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD20; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS; RITUXIMAB;

EID: 85050579810     PISSN: None     EISSN: 17582032     Source Type: Journal    
DOI: 10.2217/nmt.15.67     Document Type: Review

References (0)